Henryk Barthel,Alexander Drzezga
Henryk Barthel
Efficacy, Safety, Blood Kinetics, and 213Bi Distribution Studies of [225Ac]Ac-SibuDAB in Prostate Cancer Patients [0.03%]
锕-225放射性药物SibuDAB治疗前列腺癌的疗效、安全性和血药浓度及铋-213分布研究
Stefan Schmitl,Elisabeth Kretschmer-Chott,Eva-Maria Patronas et al.
Stefan Schmitl et al.
225Ac-labeled (S)-ibuprofen-diaminobutyric acid-PSMA (SibuDAB) is a novel, albumin-binding compound in prostate-specific membrane antigen (PSMA)-targeted α-therapy of prostate cancer. It showed superior preclinical efficacy results to [225...
161Tb-Based Anti-L1CAM Radioimmunotherapy Shows Superior Efficacy in Eliminating Ovarian Cancer Stem Cells Compared with 177Lu in Preclinical Models of Ovarian Cancer [0.03%]
基于161Tb的抗L1CAM放射免疫治疗在卵巢癌前临床模型中显示优于177Lu，可更有效地清除卵巢癌干细胞
Tihomir Zh Todorov,Ricardo Coelho,Sharon Dellea et al.
Tihomir Zh Todorov et al.
Cancer stem cells (CSCs) are highly tumorigenic, self-renewable cells with a key role in tumor relapse, metastasis, and therapy resistance. Effective CSC-targeted therapies remain an unmet clinical need, strongly dependent on the selection ...
Imaging Efficacy of [18F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath-A Phase 3, Prospective Multicenter Study [0.03%]
[18F]CTT1057正电子发射断层扫描/计算机体层成像在生物复发性前列腺癌患者中的疗效：GuidePath-AⅢ期前瞻性多中心研究结果
Stefano Fanti,Javier Jesus Robles Barba,Spencer Behr et al.
Stefano Fanti et al.
Improved diagnostic accuracy in patients with prostate cancer at first biochemical recurrence (BCR) with low prostate-specific antigen (PSA) levels is needed. This prospective study (GuidePath; NCT04838613) aimed to evaluate the imaging per...
Imaging Efficacy of [18F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study [0.03%]
[18F]CTT1057 PET在前列腺癌阳性肿瘤检测中的疗效：与病理结果对照的前瞻性多中心研究结果（GuideView II/III期临床试验）
Andrei Iagaru,Jose F Suarez,Spencer Behr et al.
Andrei Iagaru et al.
[18F]CTT1057 is a highly selective prostate-specific membrane antigen (PSMA)-targeted PET radiotracer for prostate cancer (PCa) detection. This prospective study (GuideView, NCT04838626) evaluates the imaging efficacy of [18F]CTT1057 PET to...
225Ac α-Pretargeted Radioimmunotherapy of Human Epidermal Growth Factor Receptor 2-Expressing Breast Cancer [0.03%]
人表皮生长因子受体2阳性乳腺癌的锕-225阿尔法放射免疫治疗
Sara S Rinne,Daniela Burnes Vargas,Shin Seo et al.
Sara S Rinne et al.
Radioimmunotherapy using 225Ac, a highly cytotoxic α-particle emitter, has potential for treating advanced breast cancer, especially human epidermal growth factor receptor 2 (HER2)-positive cases. We use a pretargeted radioimmunotherapy (P...
Meeting Upcoming Clinical and Diagnostic Needs in Oncologic Imaging: A Structured Reporting System for Fibroblast-Activation-Protein-Targeted Imaging-FAP-RADS Version 1.0 [0.03%]
肿瘤成像中的临床及诊断需求现状以及面向成纤维细胞活化蛋白靶向 imaging-fap-rads的结构报告系统的建立与应用版本1.0
Emil Novruzov,Gabriel T Sheikh,Eduards Mamlins et al.
Emil Novruzov et al.
Fibroblast activation protein (FAP)-targeted imaging has emerged as a promising diagnostic tool for various oncologic and nononcologic conditions. However, the increasing employment of FAP-targeted imaging with small-molecule radiotracers m...
Andrei Gafita,Jennifer A Schroeder,Francesco Ceci et al.
Andrei Gafita et al.
In recent years, there has been a headlong rush into the use of prostate-specific membrane antigen (PSMA)-targeted PET for the staging and restaging of men with prostate cancer (PC). To date, there have been regulatory approvals for PSMA PE...
Quantitative [89Zr]Zr-Trastuzumab PET and Diffusion- Weighted MRI for Characterization of Metastatic HER2-Positive Breast Cancer with PET/MRI [0.03%]
定量[89Zr]锆-曲妥珠单抗正电子发射断层扫描和扩散加权磁共振成像表征HER2阳性乳腺癌转移病灶的正电子发射断层扫描/磁共振成像研究
Ameer Mansur,Jonathan E McConathy,Erica Stringer-Reasor et al.
Ameer Mansur et al.
Current methods for evaluating HER2 expression in breast cancer are invasive and fail to capture spatial and temporal heterogeneity between primary tumors and metastases. Nuclear imaging allows for whole-body, noninvasive assessment of huma...
Feasibility of Short-Term Redifferentiation in Patients with Radioactive Iodine-Refractory Metastatic Thyroid Cancer [0.03%]
放射性碘难治性甲状腺癌患者的短期再分化可行性研究
Johannes von Hinten,Oliver Viering,Ralph A Bundschuh et al.
Johannes von Hinten et al.
Radioactive iodine-refractory thyroid cancer (TC) has a poor prognosis, and restoring iodine uptake is a major therapeutic goal. Recent studies have used tyrosine kinase inhibitors (TKIs) for 3-6 wk to achieve redifferentiation, but preclin...